title: Ensuring that injectable bicarbonate-buffered lidocaine-epinephrine complies with 2015 United States Pharmacopeia (USP) compounding provisions.
authors.affiliation: Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas.
authors.forename: Prescilia
authors.initials: P
authors.lastname: Isedeh
authors.affiliation: Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas.
authors.forename: M Laird
authors.initials: ML
authors.lastname: Forrest
authors.affiliation: Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas.
authors.forename: Deede
authors.initials: D
authors.lastname: Liu
authors.affiliation: Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas. Electronic address: daires@kumc.edu.
authors.forename: Daniel
authors.initials: D
authors.lastname: Aires
mesh_terms: D000779:Anesthetics, Local / Q000737:chemistry*; D001639:Bicarbonates; D002021:Buffers; D004339:Drug Compounding / Q000592:standards*; D004340:Drug Contamination; D004837:Epinephrine / Q000737:chemistry*; D008012:Lidocaine / Q000737:chemistry*
chemical_list: D000779:Anesthetics, Local; D001639:Bicarbonates; D002021:Buffers; D008012:Lidocaine; D004837:Epinephrine
keywords: International Organization for Standardization class; United States Pharmacopeia; bicarbonate-buffered lidocaine-epinephrine; compounded sterile preparations; microbial risk